This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Results of Combined Modality Therapy

Jay S. Cooper, MD; Thomas L. Borok, MD; Joseph Ransohoff, MD; Richard J. Carella, MD

JAMA. 1982;248(1):62-65.

Abstract
Multimodal treatment of malignant gliomas is routinely used at New York University Medical Center. Overall, our treatment program has resulted in survival rates of 78% at six months, 51% at one year, and 7% at five years for these high-grade brain tumors. However, various subgroups (based on tumor or host factors, or both) fared significantly better or worse than others. Particularly limited survival rates were found in patients who experienced paresis/paralysis or impaired mental function, who had tumors that were markedly anaplastic, who were elderly, or who for a variety of reasons did not receive the multimodal treatment we consider optimal.

(JAMA 1982;248:62-65)

Author Affiliations
From the Division of Radiation Oncology (Drs Cooper, Borok, and Carella) and the Department of Neurosurgery (Dr Ransohoff), New York University Medical Center.

Footnotes
Presented at the 63rd annual meeting of the American Radium Society, Phoenix, March 4-8, 1981.

Reprint requests to 566 First Ave, New York, NY 10016 (Dr Cooper).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interferon-{alpha}2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma
Dillman et al.
Neuro Oncol Duke 2001;3:35-41.
ABSTRACT